<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2012</study_start_year><condition>Colorectal Neoplasms</condition><condition>Colorectal Cancer Metastatic</condition><condition>Metastatic Colorectal Carcinoma of the Liver</condition><condition>Metastatic colorectal cancer</condition><disease>Metastatic Colorectal Cancer</disease><disease>Metastatic Colorectal Carcinoma Of The Liver</disease><disease>Colorectal Neoplasms</disease><disease>Colorectal Cancer Metastatic</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2116536</full_dataset_link><location>Singapore</location><location>Hong Kong</location><location>Czechia</location><location>United States</location><location>United Kingdom</location><location>Switzerland</location><location>Spain</location><location>Canada</location><location>South Korea</location><location>Austria</location><location>Belgium</location><location>China</location><location>Taiwan</location><location>Poland</location><location>Italy</location><location>France</location><location>Germany</location><study_start_month>1</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer</name><description>The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.</description><dates><creation>2012-01-15</creation></dates><accession>2116536</accession><cross_references><ClinicalTrials___gov>NCT01483027</ClinicalTrials___gov><EU Clinical Trials Register>2014-004619-36</EU Clinical Trials Register></cross_references></HashMap>